On the medical-industrial complex, its stenographers, and the system that isn't failing — it's working exactly as designed.
On April 22, the New York Times published a piece about four prescription drugs that may increase your dementia risk. It was careful. It was sourced. It named specific medications and summarized the research.
Exercise wasn't mentioned once.
This is not an oversight. It is an editorial posture. And the April 9 cholesterol piece — earlier screening thresholds, a medication ladder, children tested at ages 9 to 11 — confirms the pattern. So does the paper's ongoing Ozempic coverage: extensive, largely uncritical, minimal lifestyle context. Prevention appears, when it appears at all, as a buried clause. Pharmacological management is the default frame. And the structural forces that made this the default — economic, political, legislative — are never interrogated.
The Times is the most trusted daily newspaper in the country. That makes the pattern more consequential, not less.
What the Evidence Actually Shows
The UK Biobank tracked 91,000 participants. Over 300 minutes of moderate-to-vigorous exercise per week was associated with documented reductions in dementia risk through measurable biological pathways: increased BDNF (brain-derived neurotrophic factor), improved cerebral blood flow, reduced systemic inflammation, enhanced neurovascular coupling.
These aren't soft associations. BDNF fuels the growth of new neurons. VEGF promotes new blood vessel formation. IGF-1 works alongside human growth hormone to repair tissue and protect brain function. Muscles, during vigorous exercise, release myokines — signaling molecules that cross the blood-brain barrier and drive neurogenesis and synaptic plasticity. Irisin alone has been shown to stimulate BDNF expression. Cathepsin B links muscular effort directly to memory retention.
This is not a wellness influencer's talking point. Frontiers in Aging Neuroscience, Nature Reviews Neuroscience, Journal of Clinical Medicine — the peer-reviewed record is consistent and substantial.
The Times ran an article about brain health and didn't mention any of it. Instead it ran drug A versus drug B. Consumer advisory dressed as journalism.
The Cholesterol Story Is Worse
The April 9 piece on new cholesterol guidelines deserves its own reckoning.
Lower the thresholds. Test earlier. Screen children at 9–11, then again at 17–21. Begin the medication ladder sooner.
Here is the number the Times didn't print: NNT 50–200. Number needed to treat. In primary prevention — meaning people without existing cardiovascular disease — between 50 and 200 patients must be medicated to prevent a single cardiovascular event. The other 199 receive the side effects and none of the benefit. This figure comes from the Cochrane Collaboration's systematic review of statins in primary prevention (Taylor et al., 2013) and is consistent with subsequent meta-analyses published in JAMA Internal Medicine and Archives of Internal Medicine.
In cases without a genetic etiology — familial hypercholesterolemia being the documented exception, affecting roughly 1 in 250 people — elevated LDL is primarily a symptom of metabolic dysfunction driven by diet, sedentary lifestyle, and chronic stress. The Times piece treated it as a standalone condition requiring pharmaceutical correction.
The children's screening recommendation is not clinical caution. No randomized controlled trial evidence supports medicating asymptomatic children over lifestyle change. What it does is establish the youngest possible entry point into lifetime pharmaceutical management. That is market development. The Times presented it as a health guideline.
The conflicts of interest in major guideline panels are not conjecture — they are disclosed. A 2011 analysis in JAMA found that 56 percent of clinical practice guideline authors across medical specialties had direct financial ties to the pharmaceutical industry. The ACC/AHA panels that produced the cholesterol guidelines are no exception; their disclosed relationships are searchable through ProPublica's Dollars for Docs database. The question the Times did not ask is whether those conflicts shaped the thresholds.
Follow the Money
Two facts the Times will not put in the same paragraph:
The United States and New Zealand are the only high-income countries in the world that permit unrestricted direct-to-consumer pharmaceutical advertising. The European Union banned it under Directive 2001/83. The European Parliament explicitly ruled that pharmaceutical companies cannot be trusted to provide impartial health information.
The U.S. press runs their ads anyway.
More than 30 percent of major network evening news commercial time is pharmaceutical. According to Kantar Media tracking data, in Q1 of 2025 alone just ten drugs accounted for $725 million in advertising spend. The top ten pharmaceutical companies combined for over $100 billion in profit in 2024 and spent more than $5 billion on television ads.
Ozempic costs $1,000 per month in the United States. In Germany, $59. Wegovy runs $1,349 here and $92 in the United Kingdom. The difference is not manufacturing cost. It is a market structure built by advertising, lobbying, and the absence of price negotiation.
Senator Bernie Sanders and Senator Angus King introduced the End Prescription Drug Ads Now Act. It stalled. The committees that would move the bill are funded by the industry it would regulate. The American Medical Association endorsed a ban nearly a decade ago. Studies put the rate of misleading or outright false drug advertising at over 50 percent.
The Times runs the ads. Then it covers the drugs.
A Structural Note on "Just Exercise"
This is the point where someone invokes personal responsibility and the argument collapses into lifestyle advice. It shouldn't.
"Just exercise" is an insufficient answer when you're working three jobs. When your neighborhood has no park, no sidewalk, no gym you can afford. When your diet is largely ultra-processed food because agricultural subsidies have made it the cheapest option, and fresh produce costs what it costs in a food desert.
Wealth inequality is not a footnote to health outcomes. It is the health outcome. The Lancet in 2024 identified 14 modifiable dementia risk factors. Every one of them sits downstream of socioeconomic conditions.
Finland and New Zealand have developed exercise prescriptions as actual clinical pathways — structured, reimbursable, measurable. The United States has not, in part because prevention cannot be patented, and what cannot be patented is systematically underreimbursed. The average general practitioner appointment runs 15 to 18 minutes — not enough time for behavioral intervention even when the physician wants to attempt it.
The pill is often the only accessible intervention not because it works better, but because everything structural has been stripped.
That's the critique. Not the individual. The system.
The System Is Not Failing
This is the part the mainstream press cannot say.
Total U.S. pharmaceutical spending in 2022: $633.5 billion. Chronic disease rates: accelerating. The system is producing this outcome, not despite its design, but through it.
Healthy populations do not generate quarterly earnings. Chronic disease management does. Lower the diagnostic threshold, add children to the screening protocol, manage the condition for decades — this is not a failure mode. This is the revenue model.
In 2009, a study in the American Journal of Public Health put the annual death toll from lack of health insurance at 45,000 Americans. The Lancet attributed roughly 60,000 excess COVID deaths to the absence of universal coverage. The press does not ask how we pay for those deaths.
But when Sanders proposes Medicare for All — which is what most of the developed world already has in some form — the first question is always: how do we pay for it? Every nation consistently outperforming the United States in health outcomes has universal coverage, government price negotiation, and no direct-to-consumer pharmaceutical advertising.
The framing of Sanders' position as radical is not neutral. It is editorial advocacy for the status quo.
The research on exercise and brain health is stronger than the evidence behind most of the drugs that generated $633 billion last year. The mechanisms are documented. The outcomes are replicable. The cost is a decent pair of shoes.
A PCSK9 inhibitor — one of the newer cholesterol drugs the April guidelines are nudging patients toward — runs $14,000 a year.
One of these has a lobby.
Mark Blondin writes about health, politics, and the places where they intersect. He lives in Portugal.